{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:16:44Z","timestamp":1790144204552,"version":"4.0.1"},"reference-count":142,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Autoimmune hepatitis is an immune-mediated inflammatory condition of the liver of undetermined cause that affects both sexes, all ages, races, and ethnicities. Its clinical presentation can be very broad, from having an asymptomatic and silent course to presenting as acute hepatitis, cirrhosis, and acute liver failure potentially requiring liver transplantation. The diagnosis is based on histological abnormalities (interface hepatitis), characteristic clinical and laboratory findings (increased aspartate aminotransferase, alanine aminotransferase, and serum IgG concentration), and the presence of one or more characteristic autoantibodies. The large heterogeneity of these clinical, biochemical, and histological findings can sometimes make a timely and proper diagnosis a difficult task. Treatment seeks to achieve remission of the disease and prevent further progression of liver disease. First-line therapy includes high-dose corticosteroids, which are later tapered to decrease side effects, and azathioprine. In the presence of azathioprine intolerance or a poor response to the standard of care, second-line therapy needs to be considered, including mycophenolate mofetil. AIH remains a diagnostic and therapeutic challenge, and a further understanding of the pathophysiological pathways of the disease and the implementation of randomized controlled trials are needed.<\/jats:p>","DOI":"10.3390\/diagnostics14040382","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T09:04:01Z","timestamp":1707469441000},"page":"382","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Autoimmune Hepatitis: A Diagnostic and Therapeutic Overview"],"prefix":"10.3390","volume":"14","author":[{"given":"Lydia A.","family":"Mercado","sequence":"first","affiliation":[{"name":"Department of Liver Transplant, Mayo Clinic Florida, Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Gil-Lopez","sequence":"additional","affiliation":[{"name":"Department of Liver Transplant, Mayo Clinic Florida, Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razvan M.","family":"Chirila","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Mayo Clinic Florida, Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise M.","family":"Harnois","sequence":"additional","affiliation":[{"name":"Department of Liver Transplant, Mayo Clinic Florida, Jacksonville, FL 32224, USA"},{"name":"Department of Gastroenterology and Hepatology, Mayo Clinic Florida, Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2015). EASL Clinical Practice Guidelines: Autoimmune hepatitis. J. Hepatol., 63, 971\u20131004.","DOI":"10.1016\/j.jhep.2015.06.030"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1136\/gutjnl-2020-322362","article-title":"Recent advances in clinical practice: Epidemiology of autoimmune liver diseases","volume":"70","author":"Trivedi","year":"2021","journal-title":"Gut"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines from the American Association for the Study of Liver Diseases","volume":"72","author":"Mack","year":"2020","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e070201","DOI":"10.1136\/bmj-2022-070201","article-title":"Diagnosis and management of autoimmune hepatitis","volume":"380","author":"Muratori","year":"2023","journal-title":"BMJ"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3109\/00365521.2014.946083","article-title":"Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands","volume":"49","author":"Verwer","year":"2014","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/hep.510250308","article-title":"Autoimmune hepatitis in childhood: A 20-year experience","volume":"25","author":"Gregorio","year":"1997","journal-title":"Hepatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1007\/s10620-017-4675-y","article-title":"Global Disparities and Their Implications in the Occurrence and Outcome of Autoimmune Hepatitis","volume":"62","author":"Czaja","year":"2017","journal-title":"Dig. Dis. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1111\/j.1440-1746.2010.06384.x","article-title":"Population-based epidemiology study of autoimmune hepatitis: A disease of older women?","volume":"25","author":"Ngu","year":"2010","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"102280","DOI":"10.1016\/j.eclinm.2023.102280","article-title":"Global incidence and prevalence of autoimmune hepatitis, 1970-2022: A systematic review and meta-analysis","volume":"65","author":"Hahn","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/hep.32653","article-title":"Sociodemographic and geographic differences in the US epidemiology of autoimmune hepatitis with and without cirrhosis","volume":"77","author":"Bittermann","year":"2023","journal-title":"Hepatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1155\/2008\/642432","article-title":"Autoimmune hepatitis in a North American Aboriginal\/First Nations population. Autoimmune hepatitis in a North American Aboriginal\/First Nations population","volume":"22","author":"Minuk","year":"2008","journal-title":"Can. J. Gastroenterol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.cgh.2013.12.010","article-title":"Hispanics with primary biliary cirrhosis are more likely to have features of autoimmune hepatitis and reduced response to ursodeoxycholic acid than non-Hispanics","volume":"12","author":"Levy","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3109\/08916934.2011.592884","article-title":"Performance of the international classifications criteria for autoimmune hepatitis diagnosis in Mexican patients","volume":"44","author":"Alarcon","year":"2011","journal-title":"Autoimmunity"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1002\/hep.21884","article-title":"The impact of ethnicity on the natural history of autoimmune hepatitis","volume":"46","author":"Verma","year":"2007","journal-title":"Hepatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jhep.2013.10.020","article-title":"Autoimmune hepatitis in Denmark: Incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study","volume":"60","author":"Gronbaek","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1034\/j.1600-0528.2002.017401.x","article-title":"Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis","volume":"174","author":"Czaja","year":"2000","journal-title":"Immunol. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/hep.510300611","article-title":"Pediatric and adult forms of type I autoimmune hepatitis in Argentina: Evidence for differential genetic predisposition","volume":"30","author":"Pando","year":"1999","journal-title":"Hepatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/hep.1840130415","article-title":"Susceptibility to autoimmune chronic active hepatitis: Human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors","volume":"13","author":"Donaldson","year":"1991","journal-title":"Hepatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00004836-200207000-00016","article-title":"Prognosis of Symptomatic Versus Asymptomatic Autoimmune Hepatitis_A Study of 68 Patients","volume":"35","author":"Kogan","year":"2002","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1478-3231.2008.01904.x","article-title":"Features and consequences of untreated type 1 autoimmune hepatitis","volume":"29","author":"Czaja","year":"2009","journal-title":"Liver Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1080\/00365520802130183","article-title":"Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: A nationwide study","volume":"43","author":"Werner","year":"2008","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jhep.2013.10.035","article-title":"Health-related quality of life, depression, and anxiety in patients with autoimmune hepatitis","volume":"60","author":"Schramm","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0168-8278(94)80251-3","article-title":"The nature and prognostic implications of autoimmune hepatitis with an acute presentation","volume":"21","author":"Nikias","year":"1994","journal-title":"J. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/LVT.0000000000000105","article-title":"Autoimmune hepatitis presenting as acute liver failure: A 20-year retrospective review of North America","volume":"29","author":"Enke","year":"2023","journal-title":"Liver Transpl."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.cgh.2010.03.004","article-title":"Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome","volume":"8","author":"Kuiper","year":"2010","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hep.510280203","article-title":"Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: Clinical features and response to therapy","volume":"28","author":"Chazouilleres","year":"1998","journal-title":"Hepatology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2010.09.002","article-title":"Overlap syndromes: The International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue","volume":"54","author":"Boberg","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2009). EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. J. Hepatol., 51, 237\u2013267.","DOI":"10.1016\/j.jhep.2009.04.009"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1053\/jhep.2001.22131","article-title":"Autoimmune hepatitis\/sclerosing cholangitis overlap syndrome in childhood: A 16-year prospective study","volume":"33","author":"Gregorio","year":"2001","journal-title":"Hepatology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3109\/15513815.2014.898721","article-title":"Autoimmune hepatitis and primary sclerosing cholangitis in children and adolescents","volume":"33","author":"Rojas","year":"2014","journal-title":"Fetal Pediatr. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.cgh.2013.08.039","article-title":"Cholestatic phenotypes of autoimmune hepatitis","volume":"12","author":"Czaja","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/MPG.0b013e3181a1c265","article-title":"Autoimmune hepatitis","volume":"49","author":"Heller","year":"2009","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0168-8278(92)90178-R","article-title":"Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis","volume":"14","author":"Perdigoto","year":"1992","journal-title":"J. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MPG.0000000000001801","article-title":"Diagnosis and Management of Pediatric Autoimmune Liver Disease: ESPGHAN Hepatology Committee Position Statement","volume":"66","author":"Vergani","year":"2018","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/MCG.0b013e318157c614","article-title":"Characteristics and long-term prognosis of the autoimmune hepatitis\/primary sclerosing cholangitis overlap syndrome","volume":"43","author":"Kanzler","year":"2009","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/hep.23588","article-title":"Drug-induced autoimmune hepatitis: Clinical characteristics and prognosis","volume":"51","author":"Bjornsson","year":"2010","journal-title":"Hepatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1007\/s10620-011-1787-7","article-title":"Drug-induced autoimmune-like hepatitis: A diagnostic challenge","volume":"56","author":"Castiella","year":"2011","journal-title":"Dig. Dis. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1186\/1752-1947-4-311","article-title":"Autoimmune hepatitis triggered by nitrofurantoin: A case series","volume":"4","author":"Appleyard","year":"2010","journal-title":"J. Med. Case Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/bmj.312.7024.169","article-title":"Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome","volume":"312","author":"Gough","year":"1996","journal-title":"BMJ"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1136\/ard.2004.032821","article-title":"Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis","volume":"64","author":"Germano","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/hep.21095","article-title":"Drug-induced liver injury: Summary of a single topic clinical research conference","volume":"43","author":"Watkins","year":"2006","journal-title":"Hepatology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","article-title":"Features and Outcomes of 899 Patients with Drug-Induced Liver Injury: The DILIN Prospective Study","volume":"148","author":"Chalasani","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1055\/s-0034-1375959","article-title":"Drug-induced liver injury with autoimmune features","volume":"34","author":"deLemos","year":"2014","journal-title":"Semin. Liver Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2016.05.043","article-title":"Features of Autoimmune Hepatitis in Patients with Drug-induced Liver Injury","volume":"15","author":"Kosinski","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/jcp.2008.058248","article-title":"Histological patterns in drug-induced liver disease","volume":"62","author":"Ramachandran","year":"2009","journal-title":"J. Clin. Pathol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0399-8320(07)89323-7","article-title":"Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: A retrospective study of 115 cases of autoimmune liver disease","volume":"31","author":"Heurgue","year":"2007","journal-title":"Gastroenterol. Clin. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1111\/j.1572-0241.2002.07124.x","article-title":"Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery","volume":"97","author":"Buchel","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"J239","DOI":"10.1016\/j.jaut.2011.12.002","article-title":"Outcomes of pregnancy in women with autoimmune hepatitis","volume":"38","author":"Westbrook","year":"2012","journal-title":"J. Autoimmun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/j.1572-0241.2006.00479.x","article-title":"Pregnancy in autoimmune hepatitis: Outcome and risk factors","volume":"101","author":"Schramm","year":"2006","journal-title":"Am. J. Gastroenterol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1572-0241.2007.01609.x","article-title":"Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases","volume":"103","author":"Worns","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0168-8278(05)80395-2","article-title":"Interferon therapy in liver\/kidney microsomal antibody type 1-positive patients with chronic hepatitis C","volume":"21","author":"Muratori","year":"1994","journal-title":"J. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0168-8278(99)80092-0","article-title":"Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment","volume":"30","author":"Dalekos","year":"1999","journal-title":"J. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1111\/j.1478-3231.2012.02832.x","article-title":"Incidence and risk factors associated with de novo autoimmune hepatitis after liver transplantation","volume":"32","author":"Ma","year":"2012","journal-title":"Liver Int."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jaut.2018.10.023","article-title":"De novo autoimmune hepatitis\u2014Is this different in adults compared to children?","volume":"95","author":"Kerkar","year":"2018","journal-title":"J. Autoimmun."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0140-6736(97)06478-7","article-title":"De-novo autoimmune hepatitis after liver transplantation","volume":"351","author":"Kerkar","year":"1998","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/hep.510300103","article-title":"Development of autoimmune hepatitis following liver transplantation for primary biliary cirrhosis","volume":"30","author":"Jones","year":"1999","journal-title":"Hepatology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1046\/j.1365-2249.2001.01682.x","article-title":"Antibodies against glutathione S-transferase T1 (GSTT1) in patients with de novo immune hepatitis following liver transplantation","volume":"126","author":"Aguilera","year":"2001","journal-title":"Clin. Exp. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/hep.24080","article-title":"Autoimmune acute liver failure: Proposed clinical and histological criteria","volume":"53","author":"Stravitz","year":"2011","journal-title":"Hepatology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.aohep.2018.09.001","article-title":"Acute onset autoimmune hepatitis: Clinical presentation and treatment outcomes","volume":"18","author":"Aljumah","year":"2019","journal-title":"Ann. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00535-008-2254-x","article-title":"Precise histological evaluation of liver biopsy specimen is indispensable for diagnosis and treatment of acute-onset autoimmune hepatitis","volume":"43","author":"Fujiwara","year":"2008","journal-title":"J. Gastroenterol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/liv.14778","article-title":"Limitation of the simplified scoring system for the diagnosis of autoimmune Hepatitis with acute onset","volume":"41","author":"Muratori","year":"2021","journal-title":"Liver Int."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1872-034X.2011.00892.x","article-title":"Importance of computed tomography imaging features for the diagnosis of autoimmune acute liver failure","volume":"42","author":"Yasui","year":"2012","journal-title":"Hepatol. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3748\/wjg.15.578","article-title":"Hepatocellular carcinoma in patients with autoimmune hepatitis","volume":"15","author":"Teufel","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/hep.24743","article-title":"Mortality and the risk of malignancy in autoimmune liver diseases: A population-based study in Canterbury, New Zealand","volume":"55","author":"Ngu","year":"2012","journal-title":"Hepatology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s10620-012-2525-5","article-title":"Hepatocellular carcinoma and other malignancies in autoimmune hepatitis","volume":"58","author":"Czaja","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/apt.12470","article-title":"Review article: Autoimmune hepatitis\u2013current management and challenges","volume":"38","author":"Zachou","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez","year":"1999","journal-title":"J. Hepatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jhep.2009.01.020","article-title":"Autoimmune hepatitis in Italy: The Bologna experience","volume":"50","author":"Muratori","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jhep.2010.12.032","article-title":"Mycophenolate for the treatment of autoimmune hepatitis: Prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients","volume":"55","author":"Zachou","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/hep.23584","article-title":"Diagnosis and management of autoimmune hepatitis","volume":"51","author":"Manns","year":"2010","journal-title":"Hepatology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10620-010-1501-1","article-title":"Performance parameters of the conventional serological markers for autoimmune hepatitis","volume":"56","author":"Czaja","year":"2011","journal-title":"Dig. Dis. Sci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/0016-5085(93)90160-E","article-title":"Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis","volume":"105","author":"Czaja","year":"1993","journal-title":"Gastroenterology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/gut.51.2.259","article-title":"Establishment of standardised SLA\/LP immunoassays: Specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics","volume":"51","author":"Baeres","year":"2002","journal-title":"Gut"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/liv.12022","article-title":"Antibodies to soluble liver antigen in patients with various liver diseases: A multicentre study","volume":"33","author":"Efe","year":"2013","journal-title":"Liver Int."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/0016-5085(95)90215-5","article-title":"High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis","volume":"108","author":"Targan","year":"1995","journal-title":"Gastroenterology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/gut.2008.157818","article-title":"p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ","volume":"59","author":"Terjung","year":"2010","journal-title":"Gut"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/hep.510240515","article-title":"Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis","volume":"24","author":"Czaja","year":"1996","journal-title":"Hepatology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1111\/j.1572-0241.2006.00830.x","article-title":"Evaluation of F-actin ELISA for the diagnosis of autoimmune hepatitis","volume":"101","author":"Frenzel","year":"2006","journal-title":"Am. J. Gastroenterol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1136\/jcp.2005.027367","article-title":"Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis","volume":"59","author":"Granito","year":"2006","journal-title":"J. Clin. Pathol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10875-006-9045-z","article-title":"Double reactivity against actin and alpha-actinin defines a severe form of autoimmune hepatitis type 1","volume":"26","author":"Gueguen","year":"2006","journal-title":"J. Clin. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1053\/jhep.2001.24101","article-title":"Characterization of autoantibodies against uridine-diphosphate glucuronosyltransferase in patients with inflammatory liver diseases","volume":"33","author":"Bachrich","year":"2001","journal-title":"Hepatology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/hep.1840080632","article-title":"Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2","volume":"8","author":"Martini","year":"1988","journal-title":"Hepatology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jhep.2004.08.002","article-title":"Liver autoimmune serology: A consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group","volume":"41","author":"Vergani","year":"2004","journal-title":"J. Hepatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.3748\/wjg.14.3374","article-title":"Autoimmune liver serology: Current diagnostic and clinical challenges","volume":"14","author":"Bogdanos","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1016\/0016-5085(93)91081-R","article-title":"Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis","volume":"105","author":"Czaja","year":"1993","journal-title":"Gastroenterology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00000478-200404000-00006","article-title":"Autoimmune hepatitis with centrilobular necrosis","volume":"28","author":"Misdraji","year":"2004","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/j.1872-034X.2007.00125.x","article-title":"Clinical features of Japanese type 1 autoimmune hepatitis patients with zone III necrosis","volume":"37","author":"Miyake","year":"2007","journal-title":"Hepatol. Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/modpathol.2016.267","article-title":"Autoimmune hepatitis: Review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria","volume":"30","author":"Balitzer","year":"2017","journal-title":"Mod. Pathol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/hep.20732","article-title":"Autoimmune hepatitis: Effect of symptoms and cirrhosis on natural history and outcome","volume":"42","author":"Feld","year":"2005","journal-title":"Hepatology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1159\/000355238","article-title":"Autoimmune hepatitis and immunoglobulin G4-associated autoimmune hepatitis","volume":"31","author":"Yada","year":"2013","journal-title":"Dig. Dis."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/jgh3.12046","article-title":"Non-alcoholic fatty liver disease in patients with autoimmune hepatitis","volume":"2","author":"Takahashi","year":"2018","journal-title":"JGH Open"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/liv.15217","article-title":"Consensus recommendations for histological criteria of autoimmune hepatitis from the International AIH Pathology Group: Results of a workshop on AIH histology hosted by the European Reference Network on Hepatological Diseases and the European Society of Pathology: Results of a workshop on AIH histology hosted by the European Reference Network on Hepatological Diseases and the European Society of Pathology","volume":"42","author":"Lohse","year":"2022","journal-title":"Liver Int."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/hep.1840180435","article-title":"Meeting report: International Autoimmune Hepatitis Group","volume":"18","author":"Johnson","year":"1993","journal-title":"Hepatology"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/hep.22513","article-title":"Performance parameters of the diagnostic scoring systems for autoimmune hepatitis","volume":"48","author":"Czaja","year":"2008","journal-title":"Hepatology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.dld.2010.03.005","article-title":"Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: A new or a complementary diagnostic score?","volume":"42","author":"Gatselis","year":"2010","journal-title":"Dig. Liver Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jhep.2010.06.032","article-title":"Validation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patients","volume":"54","author":"Qiu","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1002\/hep.22825","article-title":"Validation of simplified diagnostic criteria for autoimmune hepatitis in Italian patients","volume":"49","author":"Muratori","year":"2009","journal-title":"Hepatology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/BF02093820","article-title":"Validation of scoring system for diagnosis of autoimmune hepatitis","volume":"41","author":"Czaja","year":"1996","journal-title":"Dig. Dis. Sci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/hep.23042","article-title":"Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease","volume":"50","author":"Yeoman","year":"2009","journal-title":"Hepatology"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jhep.2020.07.032","article-title":"Update of the simplified criteria for autoimmune hepatitis: Evaluation of the methodology for immunoserological testing","volume":"74","author":"Galaski","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cld.2023.06.004","article-title":"Diagnosis of Autoimmune Hepatitis","volume":"28","author":"Flikshteyn","year":"2024","journal-title":"Clin. Liver Dis."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"Shah","year":"2009","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_104","first-page":"445","article-title":"Prognostic value of liver fibrosis biomarkers: A meta-analysis","volume":"7","author":"Poynard","year":"2011","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jhep.2011.08.007","article-title":"Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: A step toward the truth in the absence of a gold standard","volume":"56","author":"Poynard","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jhep.2016.05.023","article-title":"Transient elastography in autoimmune hepatitis: Timing determines the impact of inflammation and fibrosis","volume":"65","author":"Hartl","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2214\/AJR.07.3504","article-title":"Feasibility of in vivo MR elastographic splenic stiffness measurements in the assessment of portal hypertension","volume":"193","author":"Talwalkar","year":"2009","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3748\/wjg.v23.i5.859","article-title":"Magnetic resonance elastography is accurate in detecting advanced fibrosis in autoimmune hepatitis","volume":"23","author":"Wang","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/apt.12592","article-title":"Review article: The prevention and reversal of hepatic fibrosis in autoimmune hepatitis","volume":"39","author":"Czaja","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1055\/s-0029-1245948","article-title":"Accuracy of VirtualTouch Acoustic Radiation Force Impulse (ARFI) imaging for the diagnosis of cirrhosis during liver ultrasonography","volume":"32","author":"Piscaglia","year":"2011","journal-title":"Ultraschall Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1055\/s-0029-1245690","article-title":"Acoustic radiation force impulse (ARFI) elastography in acute liver failure: Necrosis mimics cirrhosis","volume":"49","author":"Karlas","year":"2011","journal-title":"Z. Gastroenterol."},{"key":"ref_113","first-page":"351","article-title":"Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis","volume":"23","author":"Mehta","year":"1995","journal-title":"J. Hepatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s10620-006-9336-5","article-title":"Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis","volume":"51","author":"Czaja","year":"2006","journal-title":"Dig. Dis. Sci."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0168-8278(02)00214-3","article-title":"Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis","volume":"37","author":"Langley","year":"2002","journal-title":"J. Hepatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B Reactivation Associated with Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1111\/j.1572-0241.2006.00571.x","article-title":"Do guidelines matter? Implementation of the ACG and AGA osteoporosis screening guidelines in inflammatory bowel disease (IBD) patients who meet the guidelines\u2019 criteria","volume":"101","author":"Kornbluth","year":"2006","journal-title":"Am. J. Gastroenterol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0016-5085(03)01060-6","article-title":"American Gastroenterological Association medical position statement: Osteoporosis in hepatic disorders","volume":"125","year":"2003","journal-title":"Gastroenterology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11906-018-0812-z","article-title":"The Global Epidemic of the Metabolic Syndrome","volume":"20","author":"Saklayen","year":"2018","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/1753944717711379","article-title":"Metabolic syndrome: Pathophysiology, management, and modulation by natural compounds","volume":"11","author":"Rochlani","year":"2017","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/j.1572-0241.2007.01153.x","article-title":"Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse","volume":"102","author":"Carpenter","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/apt.13584","article-title":"A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis","volume":"43","author":"Zachou","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.3748\/wjg.v9.i12.2681","article-title":"Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: Influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC","volume":"9","author":"Geier","year":"2003","journal-title":"World J. Gastroenterol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/jhep.2003.50266","article-title":"Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis","volume":"38","author":"Hempfling","year":"2003","journal-title":"Hepatology"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1517\/14740338.7.3.319","article-title":"Safety issues in the management of autoimmune hepatitis","volume":"7","author":"Czaja","year":"2008","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2006.05.011","article-title":"Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis","volume":"45","author":"Heneghan","year":"2006","journal-title":"J. Hepatol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1053\/jhep.2002.32485","article-title":"Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: A retrospective analysis","volume":"35","author":"Czaja","year":"2002","journal-title":"Hepatology"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/apt.12042","article-title":"Systematic review: Managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs","volume":"36","author":"Selvarajah","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jhep.2009.02.026","article-title":"Rapidity of treatment response and outcome in type 1 autoimmune hepatitis","volume":"51","author":"Czaja","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/apt.15157","article-title":"Systematic review with meta-analysis: Mycophenolate mofetil as a second-line therapy for autoimmune hepatitis","volume":"49","author":"Santiago","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/MEG.0000000000001019","article-title":"A systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment","volume":"30","author":"Costabeber","year":"2018","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/apt.15248","article-title":"Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels","volume":"49","author":"Nicoll","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/j.cgh.2017.06.001","article-title":"Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients with Autoimmune Hepatitis","volume":"15","author":"Efe","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jhep.2013.09.020","article-title":"Autoimmune liver disease, autoimmunity and liver transplantation","volume":"60","author":"Carbone","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.cld.2011.08.008","article-title":"Recurrent and de novo autoimmune liver diseases","volume":"15","author":"Mendes","year":"2011","journal-title":"Clin. Liver Dis."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/lt.500040313","article-title":"Allograft rejection after liver transplantation for autoimmune liver diseases","volume":"4","author":"Hayashi","year":"1998","journal-title":"Liver Transpl. Surg."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/00007890-200008150-00014","article-title":"Increased incidence of chronic rejection in adult patients transplanted for autoimmune hepatitis: Assessment of risk factors","volume":"70","author":"Milkiewicz","year":"2000","journal-title":"Transplantation"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1007\/s10620-021-07378-4","article-title":"Advancing Biologic Therapy for Refractory Autoimmune Hepatitis","volume":"67","author":"Czaja","year":"2022","journal-title":"Dig. Dis. Sci."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jhepr.2019.10.005","article-title":"Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group","volume":"1","author":"Than","year":"2019","journal-title":"JHEP Rep."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2012.11.010","article-title":"Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis","volume":"58","author":"Schramm","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.cgh.2014.07.062","article-title":"Risk of drug-induced liver injury from tumor necrosis factor antagonists","volume":"13","author":"Bjornsson","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/14\/4\/382\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:57:59Z","timestamp":1760104679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/14\/4\/382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,9]]},"references-count":142,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["diagnostics14040382"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics14040382","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,9]]}}}